This is an automatically translated article.
Rhumacap is used under the direction of a doctor to treat pain caused by inflammation or pain after surgical procedures. When using Rhumacap, patients need to understand the drug in order to use it safely and effectively. Let's learn about the drug through the article below.1. What is Rhumacap?
What is Rhumacap? Rhumacap medicine has the main ingredient Etodolac 200mg, made in capsule form. Etodolac is a non-steroidal anti-inflammatory drug (NSAID) with antipyretic, analgesic and anti-inflammatory effects. The mechanism of action of the drug is because it inhibits the enzyme cyclooxygenase (COX) to reduce the synthesis of prostaglandins, a substance that causes an inflammatory response. This is a selective inhibitor of COX-2, on the study it was found that etodolac is more selective for cyclooxygenase 2 (COX-2 is the main enzyme involved in anti-inflammatory) than COX-1 (protects gastric mucosa).
The anti-inflammatory effect of Etodolac is more active than many clinically established NSAIDs.
2. Uses of the drug Rhumacap
The drug has anti-inflammatory and analgesic effects, so Rhumacap is indicated for use in the following cases:
Short-term or long-term treatment for signs and symptoms of rheumatoid arthritis, degenerative arthritis joint. Relieves acute pain such as postoperative pain, post-traumatic pain, acute gout attack, pain after tooth extraction, can also be used to relieve menstrual pain. Do not use Rhumacap in the following cases:
Patients with a history of hypersensitivity to Etodolac or to any component of the drug. Patients with kidney failure, heart failure, severe liver failure. The patient has a history of bleeding, gastrointestinal perforation due to NSAID use. Analgesia during coronary artery bypass graft surgery is not indicated. Patients with a history of asthma, allergic rhinitis, urticaria or allergic-type reactions to aspirin or other nonsteroidal anti-inflammatory drugs. Active peptic ulcer or a history of gastrointestinal bleeding. Women who are pregnant in the last 3 months.
3. Dosage and usage of the drug Rhumacap
Usage:
To be taken orally. Patients should take the drug with meals or after meals to reduce the impact on the gastrointestinal tract.
Dosage:
Adults: Take 400 mg/time and take 2 times/day. The maximum dose should not exceed 1200mg, with doses above 1000mg have not been evaluated. Patients with renal and hepatic impairment: Use lower doses and monitor renal function. Elderly: No dose adjustment is required at the starting dose. Children: The safety and effectiveness of etodolac have not been studied in children. Overdose:
In case of overdose symptoms include headache, nausea, vomiting, epigastric pain, gastrointestinal bleeding, diarrhea, disorientation, excitation, coma, drowsiness, dizziness , tinnitus, seizure, syncope. In case of severe overdose can lead to acute renal failure and liver damage. In case of overdose, the patient should be reduced absorption of drugs by gastric lavage, activated charcoal, symptomatic treatment and close monitoring. Monitor renal function and liver function should be closely monitored, patients should be monitored every 4 hours.
4. Undesirable effects of the drug Rhumacap
When using Rhumacap, you may also experience unwanted effects including:
The most common side effects are in the gastrointestinal tract such as stomach pain, digestive disorders. Thrombocytopenia, causing neutropenia and agranulocytosis, hemolytic anemia. Hypersensitivity reactions have been reported with NSAIDs, including: Anaphylactic reactions, anaphylaxis; Respiratory reactions such as asthma, or exacerbation of asthma, bronchospasm, difficulty breathing; Mixed skin disorders, including skin rash, pruritus, urticaria, cutaneous purpura, angioedema, more severe exfoliative, toxic epidermal necrolysis, erythema multiforme. Depression, headache, dizziness, insomnia or somnolence, hallucinations, disorientation, confusion, paresthesia, tremor, weakness, nervousness, aseptic meningitis (especially in immunocompromised patients) autoimmune) with symptoms such as stiff neck, headache, nausea, vomiting. Visual disturbances, optic neuritis; Tinnitus, dizziness. Edema, causing increased blood pressure, tachycardia, palpitations, heart failure. Certain NSAIDs (especially when used in high doses, for a long time) may slightly increase the risk of arterial thrombosis; vasculitis. Ulcer, perforation or possible gastrointestinal bleeding, sometimes fatal, especially in the elderly, prolonged use; Nausea, vomiting, diarrhea, epigastric pain, mouth ulcers, abdominal pain, constipation, flatulence, vomiting blood, black stools, indigestion, heartburn, rectal bleeding; exacerbation of colitis and Crohn's disease; pancreatitis. Liver dysfunction, hepatitis, jaundice; Sensitive to light. Dysuria, frequent urination, interstitial nephritis, nephrotic syndrome, renal failure. Weakness, feeling tired, malaise, fever. When you experience side effects you should stop using Etodolac and tell your doctor, with mild adverse reactions usually just stopping the drug. In case of severe hypersensitivity or allergic reaction, supportive treatment in hospital should be instituted.
5. Note when using Rhumacap
While taking Rhumacap, patients should pay attention to the following issues:
Before using the drug, you need to tell your doctor about your history of allergies, existing medical conditions. Etodolac should be used with caution in patients with fluid retention, renal impairment, renal impairment, cardiac dysfunction, liver dysfunction, hypertensive patients and the elderly. Cardiovascular thromboembolic risk with anti-inflammatory drugs: Non-steroidal anti-inflammatory drugs (NSAIDs), other than aspirin, when administered systemically, may increase the risk of cardiovascular thrombotic events, including risk of heart attack and stroke, which can lead to death. This risk may appear as early as the first few weeks of taking the drug and may increase with duration and dose. To minimize the risk of cardiac adverse events, the drug should be used at the lowest daily dose to be effective for the shortest possible time. Etodolac should be used with caution in patients with a history of bronchial asthma, as NSAIDs have been reported to cause bronchospasm in these patients. Etodolac can cause serious gastrointestinal side effects including: gastrointestinal bleeding, ulceration and perforation of the stomach, small intestine or large intestine, possibly fatal, which may be asymptomatic. . This risk should be taken into account with prolonged use or high doses. Patients should be informed of the potential warning signs and symptoms of hepatotoxicity such as nausea, fatigue, lethargy, skin itching, jaundice, and flu-like symptoms. If the above signs or symptoms appear, the patient should be instructed to stop taking the drug and seek medical attention immediately. Pregnancy: Contraindicated in the third trimester of pregnancy, given the known effects of NSAIDs on the fetal cardiovascular system. NSAIDs should not be used during the first 6 months of pregnancy or during labor, unless the potential benefit to the mother outweighs the potential risk to the fetus and mother. Lactation: Studies to date have been limited; it is possible that very low concentrations are present in breast milk. The safety of etodolac during lactation has not been established. If possible, the use of etodolac should be avoided while breastfeeding. Laboratory: A false-positive result with the bilirubin test may be possible due to the presence of phenolic metabolites in the urine.
6. Drug interactions
Some of the drug interactions that have been studied include:
Concomitant use of etodolac and other NSAIDs (including aspirin) may increase the risk of undesirable effects on the gastrointestinal tract. Antihypertensive drugs: Concomitant use may reduce the effectiveness of antihypertensive treatment. Diuretics: Reduces the diuretic effect. Diuretics may also increase the nephrotoxicity of NSAIDs. Cardiac Glycosides: NSAIDs may aggravate heart failure, decrease glomerular filtration rate and increase plasma glycosides. Lithium, methotrexate: Etodolac reduces the excretion of lithium and methotrexate and increases blood levels. Cyclosporin: Increased risk of cyclosporin nephrotoxicity. Mifepristone: NSAIDs should not be used for 8 to 12 days after taking mifepristone because they may decrease the effectiveness of mifepristone. Corticosteroids: Concomitant use increases the risk of gastrointestinal bleeding or ulceration. Anticoagulants: Nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the effect of anticoagulants. The combination of NSAIDs and warfarin may prolong prothrombin time leading to an increased risk of bleeding. Quinolone antibiotics: Increased risk of convulsions in patients taking NSAIDs with quinolones. Antiplatelet agents and selective serotonin reuptake inhibitors: If used concomitantly, attention should be paid to the risk of gastrointestinal bleeding. Store this medication in an airtight container and at room temperature, out of the reach of children.
In summary, the drug Rhacap with the main ingredient is etodolac is indicated for the treatment of pain. It should be used for the short term and at the lowest effective dose possible to reduce the risk of side effects. If you have any problems, you should talk to your doctor for advice.
Follow Vinmec International General Hospital website to get more health, nutrition and beauty information to protect the health of yourself and your loved ones in your family.
